BYSI BeyondSpring Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1677940 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY7,733.3%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE—
ROA185.0%
ROIC (approx.)—
Asset turnover0.00x
Leverage & solvency
Liabilities / assets23.2%
Debt / equity0.00x
Current ratio0.28x
Interest coverage—
Cash quality & payout
Operating cash flow / net income-0.35x
Accruals ratio250.5%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $0 | $0 | $0 | $1.35M | $1.35M |
| R&D expense | $4.39M | $2.64M | $7.27M | $25.58M | $36.89M |
| SG&A expense | $4.56M | $6.11M | $7.81M | $13.01M | $30.70M |
| Operating income | -$8.95M | -$8.75M | -$15.08M | -$37.24M | -$66.24M |
| Interest expense | — | — | — | $17,000 | $87,000 |
| Pretax income | -$8.62M | -$8.77M | -$13.92M | -$36.12M | -$64.64M |
| Income tax | $90,000 | $96,000 | -$92,000 | $163,000 | $3.57M |
| Net income | -$1.01M | -$11.12M | -$21.03M | -$33.28M | -$64.18M |
| EBITDA | -$8.86M | -$8.47M | -$14.78M | -$37.01M | -$66.18M |
| EPS (basic) | -0.02 | -0.28 | -0.54 | -0.85 | -1.64 |
| EPS (diluted) | — | — | — | — | -1.64 |
| Weighted avg. shares (diluted) | — | — | — | — | 39.02M |
| Balance sheet | |||||
| Cash & equivalents | $2.97M | $2.00M | $15.34M | $27.52M | $41.62M |
| Short-term investments | $1.00M | $0 | $193,000 | $2.87M | $30.74M |
| Current assets | $20.88M | $28.58M | $18.42M | $38.52M | $75.12M |
| PP&E, net | $155,000 | $239,000 | $317,000 | $1.87M | $1.42M |
| Total assets | $25.93M | $34.31M | $24.81M | $46.22M | $81.65M |
| Current liabilities | $13.58M | $11.01M | $7.96M | $7.35M | $15.15M |
| Short-term debt | — | — | — | $0 | $1.57M |
| Long-term debt | — | — | — | — | $0 |
| Total debt | — | — | — | — | $1.57M |
| Total liabilities | $49.92M | $48.60M | $48.27M | $49.23M | $55.27M |
| Shareholders' equity | -$32.16M | -$32.90M | -$26.80M | -$5.98M | $26.68M |
| Net debt | — | — | — | — | -$40.06M |
| Shares outstanding | 41.12M | 40.32M | 39.03M | 39.00M | 38.93M |
| Cash flow statement | |||||
| Operating cash flow | -$19.77M | -$16.44M | -$16.47M | -$27.46M | -$47.24M |
| Capital expenditure | $50,000 | $224,000 | $100,000 | $34,000 | $2.84M |
| Free cash flow | -$19.82M | -$16.67M | -$16.57M | -$27.50M | -$50.09M |
| Investing cash flow | $10.79M | -$12.01M | -$100,000 | $17.56M | -$20.41M |
| Financing cash flow | $4.97M | $26.79M | $4,000 | $3.43M | $1,000 |
| Depreciation & amortization | $87,000 | $285,000 | $302,000 | $232,000 | $61,000 |
| Stock-based compensation | $722,000 | $2.25M | $770,000 | $1.67M | $3.15M |
Free plan shows the latest 5 periods; Pro shows all 12 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.